PeptideStack
5.2kquestions
20kanswers
220users

What is the reported incidence of constipation on cagrilintide in REDEFINE-1?

Asked 10 May 2025Modified 11 months agoViewed 26k times
26

What I am working with: constipation · cagrilintide · REDEFINE-1.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What would I need in addition before this supported a decision?

constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
shareeditfollowflag
TW
askedtare_and_weigh12k1610 May 2025

5 Answers

Accepted answer first, then by votes
29

Accepted answer

Take it from the REDEFINE-1 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.

Start with the three inputs: fibre grams, fluid volume and physical activity. Most cases resolve on the first two.

Soluble fibre — psyllium, oats, legumes — holds water and softens stool. Insoluble fibre adds bulk and speeds transit. In slowed-transit constipation the soluble kind is generally the more useful of the two.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Red flags that change this from a management question to a clinical one: no bowel movement for several days with abdominal distension and vomiting, blood in the stool, or unexplained weight loss beyond what is expected.

Osmotic laxatives such as macrogol have the strongest evidence base for chronic constipation and are first-line in most guidelines.

Nothing here is medical advice.

Osmotic first, stimulant reluctantly, and not as a standing arrangement.

edited 15 Jun 2025 by Dr_Tomas_Kral — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
DK
answered · acceptedDr_Tomas_Kral53k3831 May 2025
The distinction between escalation-related and steady-state is the useful part. – leonid_marchuk 2 months ago
This should be linked from the help pages. – laminar_bench 10 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
29

Answering this needs the actual fibre and fluid intake, and people are almost always taking less of both than they think.

Osmotic agents such as macrogol draw water into the lumen and are the usual first pharmacological step; they work with the mechanism rather than against it.

Adding fibre without adding fluid produces a larger, drier, harder stool and makes the problem worse. The fluid is not optional and is the step people skip.

Research-use compounds are not approved for human use.

This one does not attenuate with tolerance. Plan for it rather than waiting it out.

shareimprove this answerflag
IB
answeredilaria_bertone33k386 Sept 2025
18

The short version: fibre to 25 to 30 grams a day, fluid to match, movement daily, and osmotic laxatives if that is insufficient.

Physical activity has a modest but real effect on transit time and is free, which makes it worth including even though it will not fix this on its own.

Aim for 25 to 30 grams of fibre a day, which requires deliberate planning at a reduced total intake because fibre-rich foods are bulky and satiating exactly when appetite is suppressed.

Physical activity has a small measurable effect on colonic transit time in controlled studies.

25 to 30 grams a day, deliberately planned, because it will not happen by accident.

shareimprove this answerflag
DK
answeredDr_Tomas_Kral53k3820 May 2025
8Any published figure for how long the constipation persists, given it does not attenuate? – tobias_maartens 25 days ago
add a comment
12

The honest answer is that this needs an active plan rather than waiting, since it does not usually resolve on its own.

Stimulant laxatives are effective and are not a first choice for a problem that is going to persist for months, because of tolerance and dependence concerns with regular use.

Pain, distension and vomiting together are urgent. That is not constipation.

shareimprove this answerflag
DB
answeredDr_Ingrid_Baumgartner73k5812 Jun 2025
6Thank you — this is the answer I was looking for. – e_dziedzic 5 months ago
add a comment
8

Severe abdominal pain with no bowel movement and vomiting is a different problem entirely and is urgent.

Magnesium-containing preparations act osmotically and are widely used; they are a laxative rather than a supplement in this context, and the dose is what makes the difference.

Fibre and fluid together. Fibre alone makes it worse and that is the commonest mistake.

shareimprove this answerflag
RC
answeredRP_C18105k34823 Jun 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.